The relationship between heparin level and activated clotting time in the adult cardiac surgery population

Perfusion

Volumn 24, Issue 2, 2009, Pages 93-96

  FitzGerald, Daniel J ^a,b   Patel, A ^a   Body, S C ^a   Garvin, S ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b NONE   (United States)

Author keywords

Activated coagulation time; Anticoagulants administration and dosage; Anticoagulation; Cardiopulmonary bypass; Heparin; Intraoperative care

Indexed keywords

HEPARIN;

ADULT; AGED; ARTICLE; BLOOD CLOTTING PARAMETERS; BLOOD CLOTTING TIME; BOLUS INJECTION; CARDIOPULMONARY BYPASS; CORRELATION ANALYSIS; DESCRIPTIVE RESEARCH; DRUG BLOOD LEVEL; FEMALE; HEPARIN PROTAMINE TITRATION; HEPARINIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL;

ADULT; AGED; AGED, 80 AND OVER; BLOOD COAGULATION; CARDIOPULMONARY BYPASS; FEMALE; HEART FAILURE; HEPARIN; HUMANS; MALE; MIDDLE AGED; WHOLE BLOOD COAGULATION TIME;

EID: 68549133389     PISSN: 02676591     EISSN: None     Source Type: Journal    
DOI: 10.1177/0267659109106729     Document Type: Article

References (17)

1. Gibbon, JH Jr. Application of a mechanical heart and lung apparatus to cardiac surgery. Minn Med 1954; 37: 171-185.
2. Bull, BS, Huse, WM, Brauer, FS, Korpman, RA. Heparin therapy during extracorporeal circulation II. The use of a dose-response curve to individualize heparin and protamine dosage. J Thorac Cardiovasc Surgery 1975; 69: 685-689.
3. Hattersley, PG. Activated coagulation time of whole blood. JAMA 1966; 196: 436-440.
4. Bull, BS, Korpman, RA, Huse, WM, Briggs, BD. Heparin during extracorporeal circulation I. Problems inherent in existing protocols. J Thorac Cardiovasc Surgery 1975; 69: 674-684.
5. Hepcon HMS Plus Hemostasis Management System. Operators Manual 2002; 5: 12-14.
6. Allen, TH. Peng, MT, Chen, KP, Huang, TF, Chang, C, Fang, HS. Prediction of blood volume and adiposity in man from body weight and cube of height. Metabolism 1956; 5: 328.
7. Culliford, AT, Gitel, SN, Starr, N, et al. Lack of correlation between activated clotting time and plasma heparin during cardiopulmonary bypass. Ann Surg 1981; 193: 105-111.
8. Despotis, GJ. Comparison of activated coagulation time and whole blood heparin measurements with laboratory plasma anti-Xa heparin concentration in patients having cardiac operations. J Thorac Cardiovasc Surgery 1994; 108: 1076-1082.
9. Despotis, GJ, Joist, JH, Hogue, CW Jr, et al. The impact of heparin concentration and activated clotting time monitoring on blood conservation. A prospective, randomized evaluation in patients undergoing cardiac operation. J Thorac Cardiovasc Surgery 1995; 110: 46-54.
10. Thomas, DP, Barrowcliffe, TW, Johnson, EA. The influence of tissue source, salt and molecular weight on heparin activity. Scand J Haematol 1980; 25(Suppl. 36): 40-48.
11. Walton, PL, Ricketts, CR, Bangham, DR. Heterogeneity of heparin. Br J Haematol 1966; 12: 310-325.
12. Marciniak, E, Farley, CH, DeSimone, PA. Familial thrombosis due to antithrombin III deficiency. Blood 1974; 43: 219-231.
13. Hiebert, LM, Jaques, LM. The observation of heparin on endothelium after injection. Thromb Res 1976; 8: 195-204.
14. Mabry, CD, Read, RC, Thompson, BW, Williams, GD, White, HJ. Identification of heparin resistance during cardiac and vascular surgery. Arch Surg 1979; 114: 129-134.
15. Gravlee, GP, Rogers, AT, Dudas, LM. Heparin management protocol for cardiopulmonary bypass influences postoperative heparin rebound but not bleeding. Anesthesiology 1992; 76: 393-401.
16. Koster, A, Fischer, T, Praus, M. Hemostatic activation and inflammatory response during cardiopulmonary bypass: Impact of heparin management. Anesth Analg 2002; 97: 837-841.
17. Ammar, T, Fisher, CF, Sarier, K, Coller, BS. The effects of thrombocytopenia on the activated clotting time. Anesth Analg 1996; 83: 1185-1188.